Aurobindo Pharma, MSN Labs seek DGCI nod for Phase-III trials of Merck's molnupiravir

In a meeting held on October 4, both the companies said that they “they want to discontinue phase III trial in moderate Covid-19 patients and continue the phase III trial in mild Covid patients", as per the minutes of the meeting. ET has seen the minutes of the SEC meeting.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3FtQi20
via IFTTT